Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Milford, Ohio Clinical Trials

A listing of Milford, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (11) clinical trials

Open-Label Randomised Multi-Drug Biomarker-Directed Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, randomised Phase 1b study in patients with muscle invasive bladder cancer (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetics and anti-tumour activity of multiple agents as monotherapy and as ...

Phase

6.13 miles

Learn More »

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer

The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).

Phase

8.13 miles

Learn More »

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.

Phase

8.13 miles

Learn More »

Atezolizumab Pemetrexed Disodium Cisplatin and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

PRIMARY OBJECTIVES: I. To evaluate if the regimen of neoadjuvant cisplatin-pemetrexed disodium (pemetrexed)-atezolizumab, surgery +/- radiation, then maintenance atezolizumab is feasible and safe for patients with resectable malignant pleural mesothelioma. SECONDARY OBJECTIVES: I. To evaluate progression free survival (both by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and also ...

Phase

8.13 miles

Learn More »

A Study of the Safety Tolerability and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults

This study will assess the safety, tolerability, and pharmacokinetic profile of RTA 901 following escalating single and multiple oral doses of RTA 901 in healthy adult subjects. This first-in-human, Phase 1, single-center study consists of single ascending doses (SAD) and multiple ascending doses (MAD) conducted in 2 parts. Part 1 ...

Phase

8.21 miles

Learn More »

A Phase 1 Study to Evaluate HTI-2088 Tablet

This is a single-center, randomized, double-blind, placebo-controlled, single ascending dose trial with single oral doses of HTI-2088 tablets to subjects at 3 levels (2.5, 3.75, 5 mg). Ten subjects will be enrolled at each dose level, randomized within groups at an active: placebo ratio of 4:1.

Phase

8.21 miles

Learn More »

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

Twenty healthy subjects will be allocated 4:1 to either the crossover study groups (16 subjects) or to the 0.25 mg tablet single dose treatment (4 subjects). Subjects allocated to the crossover study groups will be randomized 1:1 to 0.5 mg tablet/capsule (8 subjects) or 1.0 mg tablet/capsule (8 subjects). Within ...

Phase

8.21 miles

Learn More »

A Multiple Ascending Dose Study of COR388

The study will enroll 3 cohorts of 8 healthy subjects 55 and 80 years of age at the Clinical Pharmacology Unit (CPU) and 1 cohort of 12 AD subjects 55 and 80 years of age. Subjects in cohorts 1-3 will receive the study drug or placebo for 10 consecutive days ...

Phase

8.21 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.

Phase

8.54 miles

Learn More »

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon the following cancer diagnosis: Non-small cell ...

Phase

8.58 miles

Learn More »